BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease
Portfolio Pulse from Benzinga Newsdesk
BioLineRx announced a multi-center Phase 1 trial sponsored by St. Jude Children's Research Hospital to evaluate Motixafortide for CD34+ hematopoietic stem cell mobilization in gene therapy applications for sickle cell disease.
May 30, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioLineRx's announcement of a Phase 1 trial for Motixafortide in collaboration with St. Jude Children's Research Hospital is a significant step in advancing gene therapy for sickle cell disease.
The collaboration with a reputable institution like St. Jude and the initiation of a Phase 1 trial for a promising therapy can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100